Velusetrag
- Generic Name
- Velusetrag
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H36N4O5S
- CAS Number
- 866933-46-2
- Unique Ingredient Identifier
- J4VNV64ARB
- Background
Velusetrag has been used in trials studying the treatment of Gastroparesis and Alzheimer's Disease. It is a highly selective serotonin receptor agonist effective in patients with chronic constipation. It is being developed by Theravance. Velusetrag was discovered by Theravance through the application of its multivalent drug design in a research program dedic...
- Associated Conditions
- -
- Associated Therapies
- -
Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 17
- Registration Number
- NCT05724069
- Locations
- 🇧🇪
UZ Leuven Gasthuisberg Campus, Leuven, Belgium
🇮🇹Policlinico S.Orsola-Malpighi, Bologna, Italy
🇮🇹Aou Arcispedale Sant'Anna Di Cona, Cona, Italy
The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 233
- Registration Number
- NCT02267525
Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 40
- Registration Number
- NCT01467726
- Locations
- 🇺🇸
Comprehensive Clinical Development, Miramar, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath